A Phase 3 Multi-center Randomized Double-blinded Study of MK-7684 with Pembrolizumab as a Co-formulation (MK-7684A) Versus Pembrolizumab Monotherapy as a First Line Treatment for Participants with PD-L1 Positive (TPS>=1%) Metastatic Non-Small Cell Lung Cancer

Brief description of study

This is a Phase 3 randomized, active-controlled, parallel-group, multi-site, double-blind study of MK-7684A versus pembrolizumab. Participants with metastatic Stage IV NSCLC with no previous treatment for Stage IV disease and PD-L1 positive tumors (TPS =1%) will be enrolled in the study. This study will be conducted in participants with measurable disease in whom EGFR-, ALK-, or ROS1-targeted therapy is not indicated.


Clinical Study Identifier: s20-01730
ClinicalTrials.gov Identifier: NCT04738487
Principal Investigator: Marissa Rybstein.
Other Investigators: Danny Perlaza, James Newman, Jeffrey G Schneider, Elka R Travis.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.